SGX:H02Pharmaceuticals
Haw Par (SGX:H02) 99% Net Margin Reinforces Bullish Profitability Narratives
Haw Par (SGX:H02) FY 2025 Earnings Snapshot
Haw Par (SGX:H02) has released its FY 2025 scorecard with first half revenue of S$126.3 million and basic EPS of S$0.651, alongside trailing twelve month revenue of S$230.0 million and EPS of S$1.199 that frame the latest numbers in a fuller earnings context. The company reported revenue moving from S$118.1 million to S$126.7 million across the FY 2024 halves, while basic EPS shifted from S$0.551 to S$0.480. This gives investors a clearer view of...